Expert Interview
A Second Look: Discussing the use of Verquvo following its FDA approval to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction less than 45%
Ticker(s): MRKInstitution: Sharp HealthCare San Diego
- Interventional cardiologist fellowship trained at Northwestern.
- Treats 300 patients with chronic heart failuer and has prescribed Verquvo for 5 patients.
- Has numerous publications and grants, with a specific focus on novel therapeutic procedures in patients with structural heart disease and high-risk coronary interventions.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
